Poland Breast Cancer Therapeutics Market Analysis Report 2022 to 2030

Poland Breast Cancer Therapeutics Market Analysis

$ 3999

Poland's breast cancer therapeutics market size is expected to witness growth from $106 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the forecasted year 2022-30. The major market drivers for Poland's breast cancer therapeutics market are increased are rapid advancements in treatment options and the increasing incidence of breast cancer in Poland. The market is segmented by therapy, by cancer type, and by distribution channel. Some leading companies in Poland's breast cancer therapeutics market are Polpharma, Bristol-Myers Squibb, and Eli Lilly.

ID: IN10PLPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Poland AUTHOR: Parul Choudhary

Buy Now

Poland Breast Cancer Therapeutics Market Executive Analysis

Poland's breast cancer therapeutics market size is at around $106 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. Budget receipts are projected at $111.31 Bn and expenditures at $118.48 Bn in 2022. This results in a $7.14 Bn budget deficit for the national government. This year, the general government deficit is expected to drop from 5.3% of GDP to 2.8%. The Polish Parliament passed a bill requiring the state budget to set aside funds for health care funding in the amount of no less than 7% of GDP annually, with no less than 5.30% of GDP in 2021 and 5.75% in 2022.

Every year in Poland, more than 5,000 women die from breast cancer and over 15,000 new cases are identified. The American National Cancer Institute estimates that a woman's lifetime risk of developing breast cancer is 12% and rises with age. Most cases are observed in women between the ages of 50 and 69. The clinical stage of the tumour determines the likelihood of a successful course of treatment for breast cancer. Early diagnosis is therefore essential for survival and improves treatment outcomes. The ability and resources of the health system, awareness, and access to screening and care are a few aspects that are important for early diagnosis. The Polish parliament passed the National Strategy for Oncology 2020–2030 plan. The strategy focuses national efforts on achieving UN objectives through enhancing population screening programmes, evidence-based prevention, efficient cancer therapies, and palliative care for cancer patients. Through registries that save, display, and analyse data to prioritise and track cancer control efforts, the programme aims to increase cancer survival and encourage cancer epidemiological monitoring.

poland breast cancer therapeutics market

Market Dynamics

Market Growth Drivers

Being the most prevalent cancer in the world, breast cancer will continue to fuel the growth of the Poland breast cancer therapeutics market. As more people are diagnosed with breast cancer worldwide, there is a growing demand for effective and precise therapy for those who have the disease. Future innovative therapies will be attainable as a result of the leading market participants' strong tendency toward ongoing research and development in the field of breast cancer therapeutics. The introduction of cutting-edge treatments like immunotherapies and targeted medicines is anticipated to greatly accelerate the growth of the Polish market.

Market Restraints

The Poland breast cancer therapeutics market for breast cancer medications is being constrained by unfavourable side effects brought on by drug use along with the high cost of treatment of targeted therapies and hormonal therapies in Poland.

Competitive Landscape

Key Players

Neuca (POL)
Farmacol (POL)
Polska Grupa Farmaceutyczna (POL)
Polpharma (POL)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

Every Polish citizen resident has the right to affordable healthcare, which is provided by the National Health Fund (NFZ), under the country's free public healthcare system. Every Polish citizen is required to make a payment to the organisation in the form of an 8.5% deduction from their own income. The majority of the money for publicly funded, cost-free health insurance comes from these deductions. The National Health Fund is in charge of organising and funding healthcare in Poland, including the treatment of breast cancer. For women aged 50 to 69, the NFZ has launched a national breast cancer screening programme that includes mammography every two years. Women who have a higher risk of getting breast cancer, like those with a family history of the condition, may be eligible for earlier and more regular screenings. Surgery, radiation therapy, and chemotherapy are all available treatment options for breast cancer in Poland.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Poland Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.